Epstein Secrets

rill Lynch, Pierce, Fenner & Smith Incorporated The power of global connectionsTM From: Ens, Amanda Sent: Wednesday, August 24, 2016 3:30 PM To: 'Richard Kahn' Subject: RE: TEVA...IPR Decision Coming By Thurs...I like the Risk/Reward (+10% vs -5%) Rich, right after I sent this, the ruling came in earlier a

Jeffrey E." <[email protected]> To: Richard Kahn Subject: Re: Add to TEVA and AGN Date: Thu, 25 A

pportunity. AGN A Pfd: $861.00 (6.4% strip yield) TEVVF Pfd: $883.25 (8.1% strip yield) EFTA00820341 With TEVA confirming the loss on 2 of its 5 Copaxone patents from yesterday's IPR decisions & MYL confirming that the third IPR decision is expected by 1-Sept, our analyst Sumant has notes out on TEVA,

rill Lynch, Pierce, Fenner & Smith Incorporated The power of global connections"' From: Ens, Amanda Sent: Wednesday, August 24, 2016 3:30 PM To: 'Richard Kahn' Subject: RE: TEVA...IPR Decision Coming By Thurs...I like the Risk/Reward (+10% vs -5%) Rich, right after I sent this, the ruling came in earlier a

"Jeffrey E." <[email protected]> To: Richard Kahn Subject: Re: Add to TEVA and AGN Date: Thu, 25 A

pportunity. AGN A Pfd: $861.00 (6.4% strip yield) EFTA00820350 TEVVF Pfd: $883.25 (8.1% strip yield) With TEVA confirming the loss on 2 of its 5 Copaxone patents from yesterday's IPR decisions & MYL confirming that the third IPR decision is expected by 1-Sept, our analyst Sumant has notes out on TEVA,

From: Richard Kahn c:I > To: "jeffrey EI Subject: Fwd: Allergen and Teva Date: Thu, 28 Jul 2016 17:47:26 +0000 Wadi merits: agn.pdf; teva.pdf; Cvt_Primer_2013_NEWEST

From: Richard Kahn c:I > To: "jeffrey EI Subject: Fwd: Allergen and

lobal generic capabilities, vertical integration into the active pharmaceutical ingredients (API) business, and a branded specialty pharma business (Copaxone, Treanda, Ai lett, Nuvigil and other products). Investment Rationale We believe Teva is a compelling investment opportunity as we like the company'

From: Richard Kahn • To: "Jeffrey E." <[email protected]> Subj

From: Richard Kahn • To: "Jeffrey E." <[email protected]> Subject: Re: Add to TEVA and AGN Date: Thu, 25 Aug 2016 16:43:38 +0000 agreed her frequent recommendati

as a buying opportunity. AGN A Pfd: $861.00 (6.4% strip yield) TEVVF Pfd: $883.25 (8.1% strip yield) With TEVA confirming the loss on 2 of its 5 Copaxone patents from yesterday's IPR decisions & MYL confirming that the third IPR decision is expected by 1-Sept, our analyst Sumant has notes out on TEVA,

From: Ens, Amanda Sent: Tuesday, February 14, 2017 3:47 PM To: jeffrey E.; Richard Kahn Subject: *TEVA 7% TEWF - Play the preferred if you believe there's a dvd cut coming Would add to your position. We have a BUY on TEVA and like bei

bruary 14, 2017 3:47 PM To: jeffrey E.; Richard Kahn Subject: *TEVA 7% TEWF - Play the preferred if

http://researchl.ml.com/C?q=OX0V-tRcQHjB6iVg2p0aPw> , limited visibility into US generic launches is a risk to TEVA's 2017 outlook (we already model Copaxone generics in 1Q17). That said, we continue to like the risk/reward on the shares especially if Teva could execute against somewhat reset expectations